A Randomized Double-blind Phase II Study Evaluating the Role of Maintenance Therapy With Cabozantinib in High Grade Undifferentiated Uterine Sarcoma (HGUS) After Stabilization or Response to Doxorubicin +/- Ifosfamide Following Surgery or in Metastatic First Line Treatment

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 05 Jul 2019

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cabozantinib (Primary)
Indications Sarcoma; Uterine cancer
Focus Therapeutic Use
Acronyms HGUS Study

Most Recent Events

10 Aug 2018 Planned number of patients changed from 54 to 90.
11 Oct 2016 Trial design presented at the 41st European Society for Medical Oncology Congress
27 Sep 2016 Data from this trial will be presented at the European Society for Medical Oncology (ESMO) 2016 Congress, reported in an Ipsen media release.

Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Login with a username/password associated to an account with a valid subscription
Contact your organization’s admin about adding this content to your AdisInsight subscription
Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Welcome to AdisInsight